General hospital psychiatry最新文献

{"title":"Associations between delivery modality and treatment dose and density of trauma-focused evidence-based psychotherapy for posttraumatic stress disorder","authors":"Nicholas Holder ,&nbsp;Adam Batten ,&nbsp;Brian Shiner ,&nbsp;Shira Maguen","doi":"10.1016/j.genhosppsych.2025.08.008","DOIUrl":"10.1016/j.genhosppsych.2025.08.008","url":null,"abstract":"<div><div>Recommended evidence-based psychotherapies (EBPs) for posttraumatic stress disorder (PTSD), including Cognitive Processing Therapy (CPT) and Prolonged Exposure Therapy (PE) are being delivered by video telehealth at high rates. Although clinical trials suggest that the treatment dose of PTSD EBPs is similar between in-person and video telehealth modalities, large-scale studies have not investigated whether this remains consistent in routine clinical practice. To fill this gap, we identified a national sample of veterans who initiated PTSD EBP from 4/2022–4/2023 (<em>n</em> = 23,812) in the Veterans Health Administration (VHA). We measured adequate dose (receipt of eight or more in six months) and treatment density (number of sessions in 14 weeks) of PTSD EBP. We used Bayesian hierarchical logistic regression (for the dichotomous adequate dose outcome) and negative binomial regression (for the count density outcome) to understand the risk-adjusted differences in treatment dose and density across delivery modalities. Veterans who received at least half of their PTSD EBP via video telehealth had a higher risk-adjusted odds of receiving an adequate dose compared to in-person treatment (MPOR = 1.19, 90 %CI = 1.10, 1.29; ROPE = 44.0 %); however, treatment density was similar across modalities (MPRR = 0.98; 90 % CI = 0.91, 1.05). Interactions suggested slightly worse metrics in PE delivered by video telehealth than in-person. Results suggested that PTSD EBPs can be delivered via video telehealth in routine clinical practice with similar treatment dose and density to in-person treatment. Future research is needed to understand how important correlates of treatment dose and density may interact with delivery modality.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 315-321"},"PeriodicalIF":3.7,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial","authors":"Margaret L. Ross ,&nbsp;Ravi Iyer ,&nbsp;Martin L. Williams ,&nbsp;Mark Boughey ,&nbsp;Clare O'Callaghan ,&nbsp;Richard Hiscock ,&nbsp;Justin Dwyer","doi":"10.1016/j.genhosppsych.2025.08.001","DOIUrl":"10.1016/j.genhosppsych.2025.08.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Importance&lt;/h3&gt;&lt;div&gt;Psilocybin-assisted psychotherapy may offer a novel approach to treating depression, anxiety, and existential distress in individuals with life threatening illnesses, where current treatments show limited efficacy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the efficacy and safety of psilocybin-assisted psychotherapy versus active placebo and psychotherapy in adults with life-threatening illnesses.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Double-blind, randomized controlled phase 2b trial (RCT) with an open-label extension and 6-month follow-up (January 2020 – October 2023).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting&lt;/h3&gt;&lt;div&gt;Single-site study at a tertiary hospital's palliative care department (St. Vincent's Hospital Melbourne affiliated with the University of Melbourne).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Adults aged 18–80 with a life-threatening illness and clinically significant depression and/or anxiety.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interventions&lt;/h3&gt;&lt;div&gt;Participants were randomized to receive 25 mg psilocybin or 100 mg niacin (active placebo), alongside three preparatory psychotherapy and six post-dose integration psychotherapy sessions. After 6–7 weeks post double blind dose, all participants received 25 mg psilocybin in an open-label extension, enabling a two dose versus one dose group comparator. Participants were followed up to 26 weeks post open label dose.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main outcomes and measures&lt;/h3&gt;&lt;div&gt;Primary outcome was change in depression and anxiety symptoms, assessed using the Hospital Anxiety and Depression Scale (HADS), from baseline to 6–7 weeks post-dose. Key secondary outcomes included the Beck Depression Inventory-II (BDI-II) and the State-Trait Anxiety Inventory – State version (STAI-S), which provided complementary, dimensional measures of depression and anxiety over the same time period.&lt;/div&gt;&lt;div&gt;Additional secondary outcomes included Death Attitudes Profile, WHOQOL-BREF, State-Trait Anxiety Inventory (STAI-Trait scale), Mystical Experiences Questionnaire, and Persisting Effects Questionnaire. Exploratory outcomes included spiritual well-being, hopelessness, demoralization, and HADS-Trait scores.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Thirty-five participants (mean age 56.0; 54.3 % female) were randomized (psilocybin: n = 17; placebo: n = 18). At 6–7 weeks, psilocybin produced significantly greater reductions in HADS depression (B = –2.49; P = .02; d = 1.12), BDI-II (B = –7.56; P = .004; d = 2.97), and STAI-State anxiety (B = –12.59; P = .005; d = 4.51) compared to placebo. Benefits were sustained at 26 weeks. Exploratory outcomes demonstrated enhanced spiritual well-being, quality of life, and significant reductions in demoralization, death anxiety and hopelessness. No serious treatment-emergent adverse events occurred. Psilocybin was associated with more mild-to-moderate adverse events. One participant withdrew due to anxiety during dosing.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions and relevance&lt;/h3&gt;&lt;div","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 322-331"},"PeriodicalIF":3.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-related stigma and bias in mental health care guidelines: Critical appraisal of international government documentation addressing the physical health needs of individuals living with mental illness","authors":"Melissa Eaton ,&nbsp;Yasmine Probst ,&nbsp;Laura Robinson ,&nbsp;Rebecca George","doi":"10.1016/j.genhosppsych.2025.08.007","DOIUrl":"10.1016/j.genhosppsych.2025.08.007","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 290-292"},"PeriodicalIF":3.7,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144878185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depressive symptoms and cognitive function trajectories in frail middle-aged and older adults: A longitudinal analysis based on the CHARLS cohort (2011–2018)","authors":"Ze Chang ,&nbsp;Xiaoxuan Cao ,&nbsp;Xueru Zhang ,&nbsp;Yunmeng Chen,&nbsp;Liuding Wang,&nbsp;Yunfan Zhang,&nbsp;Jingjing Wei,&nbsp;Xiao Liang,&nbsp;Yunling Zhang","doi":"10.1016/j.genhosppsych.2025.08.006","DOIUrl":"10.1016/j.genhosppsych.2025.08.006","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;With the global aging of the population, the interaction between frailty syndrome in middle-aged and elderly people, depressive symptoms, and cognitive decline has attracted increasing attention. The vicious cycle formed by these three factors significantly reduces quality of life and increases the burden on medical care. Currently, there is still insufficient longitudinal evidence in China on the dynamic relationship between depressive symptoms and cognitive function in frail populations&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;div&gt;A total of 1279 middle-aged and elderly people who met the criteria for frailty were included in the study based on data from the China health and retirement longitudinal study (CHARLS) from 2011 to 2018. Group-based trajectory modeling (GBTM) was used to identify cognitive function trajectories, and model fitting was evaluated using indicators such as Bayesian information criterion (BIC) and average posterior probability. A multivariable logistic regression model was used to analyze the association between depressive symptoms in frail individuals and different cognitive trajectories, adjusting for confounding factors such as demographic characteristics and comorbid chronic diseases&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;This study identified six cognitive function development trajectories and analyzed the association between depressive symptoms and different cognitive trajectories. The results showed that, compared with the cognitive Normal-stable group, depressive symptoms were significantly associated with all adverse cognitive trajectories. In the unadjusted model, depressive symptoms increased the risk of the cognitive impairment-rapid decline group by 1.72 times (OR = 2.72, 95 % CI 1.56–4.72) and increased the risk of the cognitive Normal-late rapid decline group by 0.95 times (OR = 1.95, 95 % CI 1.19–3.18). After adjusting for multiple factors, this association remained significant. In the fully adjusted model (model 5), the risk for the cognitive impairment-rapid decline group further rose to 2.10 times (OR = 3.10, 95 % CI 1.69–5.69), while the risk for the cognitive impairment-persistent low level group (OR = 1.69, 95 % CI 1.05–2.72), the cognitive Normal-fluctuating group (OR = 1.65, 95 % CI 1.03–2.62), and other adverse trajectory groups also showed significant associations (all &lt;em&gt;p&lt;/em&gt; &lt; 0.05). These results indicate that depressive symptoms are an independent risk factor for multiple adverse cognitive function trajectories, with the strongest association observed in the rapid cognitive decline group&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This study found that depressive symptoms are an independent risk factor for cognitive decline in middle-aged and elderly frail populations, particularly significantly predicting rapid cognitive decline and persistent cognitive impairment. Depressive symptom screening demonstrates significant clinical value in cognitive health management for frail","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 282-289"},"PeriodicalIF":3.7,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and acceptability of physical activity for mental health disorder: A comprehensive umbrella review of 103 meta-analyses and systematic reviews","authors":"Liuyang Lu ,&nbsp;Mingyu Chen ,&nbsp;Jing Ren ,&nbsp;Ming Ni ,&nbsp;Yunzhe Zhou ,&nbsp;Xiaoming Li","doi":"10.1016/j.genhosppsych.2025.08.002","DOIUrl":"10.1016/j.genhosppsych.2025.08.002","url":null,"abstract":"<div><h3>Background</h3><div>Despite numerous studies investigating the efficacy and acceptability of physical activity (PA) for specific mental health disorders, comprehensive guidelines on the appropriate type, frequency, and duration of PA for each disorder remain lacking. This review aims to synthesize effect sizes and provide a thorough evaluation of the efficacy and acceptability of PA for mental health disorders.</div></div><div><h3>Method</h3><div>A comprehensive literature search was conducted across multiple databases, including PubMed, PsycINFO, Embase, Cochrane Library, and Web of Science.</div></div><div><h3>Results</h3><div>Following an extensive search and rigorous assessment, 103 articles were selected, 4268 study groups, and 364,889 participants. The combined effect size indicates a moderate effect of PA on mental health disorder: SMD = 0.534 (95 % CI 0.514 to 0.554) (class I evidence). Tai Chi or Qigong demonstrated the highest efficacy in treating mental health disorder (SMD = 0.693, 95 % CI 0.538 to 0.848) (class II evidence). Regarding acceptability, the overall dropout rate ranged from 4.5 % to 41.7 %, with most treatment groups showing similar dropout rates compared to control groups. Notably, aerobic exercise exhibited a lower dropout rate, whereas mind-body exercises and high-intensity groups had higher dropout rates. Evidence suggests a core principle of prioritizing moderate-intensity activity as the foundation—specifically, ≥3 sessions per week, each lasting 30–60 min, sustained for a total period exceeding 6 weeks.</div></div><div><h3>Conclusions</h3><div>Our study is the first to comprehensively summarize the efficacy of PA in treating mental health disorders. We provide detailed recommendations on the feasibility and acceptability of various PA modalities, tailored to different conditions. Specifically, our synthesis offers guidance on the most suitable types of PA, along with their frequencies and durations, for each specific disorder.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 264-281"},"PeriodicalIF":3.7,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapting depression collaborative care models to increase uptake of computerized cognitive behavioral therapy at the VA: A pilot randomized controlled trial","authors":"Lucinda B. Leung ,&nbsp;Catherine E. Brayton ,&nbsp;Sona Hovsepian ,&nbsp;Michael A. Karakashian ,&nbsp;Karen Chu ,&nbsp;Nicholas J. Jackson ,&nbsp;Paul G. Shekelle ,&nbsp;Alison B. Hamilton ,&nbsp;Elizabeth M. Yano ,&nbsp;Bruce L. Rollman ,&nbsp;Alexander S. Young","doi":"10.1016/j.genhosppsych.2025.07.014","DOIUrl":"10.1016/j.genhosppsych.2025.07.014","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the feasibility, acceptability, and potential health effects of computerized cognitive behavioral therapy-enhanced collaborative care (cCBT-CC) versus usual primary care (UC).</div></div><div><h3>Background</h3><div>Internet-based cCBT can effectively treat depression but is not widely used, including in the Veterans Health Administration where it was freely available for veterans. We adapted pre-existing depression collaborative care models using implementation and user-centered design strategies to facilitate cCBT implementation.</div></div><div><h3>Methods</h3><div>This pilot randomized controlled trial (RCT) included 57 VA primary care patients to cCBT-CC or UC. Participants had Patient Health Questionnaire (PHQ-9) scores of 10+. Those with serious mental illness (e.g., bipolar depression, schizophrenia) and active suicidality were excluded. Intervention patients received tailored Vets Prevail cCBT accompanied by collaborative care manager support, overseen by psychiatry and primary care. UC offered collaborative care services and digital mental health tools at baseline. Feasibility (patient reach, provider adoption, intervention implementation), acceptability (CSQ-8), and potential effectiveness (PHQ-9) data was collected at baseline and 3-months by a blinded study team member.</div></div><div><h3>Results</h3><div>Participants (cCBT-CC <em>n</em> = 29, UC <em>n</em> = 28) were 50 years old (mean); 70 % men; 32 % White, 32 % Hispanic, 25 % Black; 21 % homeless-experienced. Mean baseline PHQ-9 scores were 15.1 (SD = 5.0); 39 % reported suicidal thoughts/behaviors. 72 % of 94 primary care providers, from 6 out of the 8 participating clinics, helped support their patients' participation. cCBT-CC participants received 4 care manager check-ins over 33 days totaling 113 min (64 % clinical; 36 % technical), on average. They completed mean 6.7 out of 11 cCBT lessons. Participants in the cCBT-CC arm experienced a statistically (not clinically) significant decline in the primary outcome of depression (Δ = -2.5; <em>p</em> = 0.02) symptoms from pretreatment to posttreatment. There was a greater, albeit non-significant, decrease in PHQ-9 scores among cCBT-CC participants over 3-months, compared to UC participants (Δ = -2.8; 95 % CI = -5.6, −0.01; <em>p</em> = 0.05).</div></div><div><h3>Conclusions</h3><div>cCBT-enhanced collaborative care appeared feasible, acceptable, and possibly effective in treating primary care patients with depression.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 223-233"},"PeriodicalIF":3.7,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of mindfulness-based cognitive therapy via e-health on anxiety and depression in adults: A meta-analysis","authors":"Shizhen Wang ,&nbsp;Mengru Wu ,&nbsp;Jixiang Wei ,&nbsp;Wangjie Xia ,&nbsp;Zhen Luo ,&nbsp;Li Tian","doi":"10.1016/j.genhosppsych.2025.07.017","DOIUrl":"10.1016/j.genhosppsych.2025.07.017","url":null,"abstract":"<div><h3>Background</h3><div>Anxiety and depression are highly prevalent mental health disorders, imposing significant burdens on individuals and healthcare systems. Mindfulness-based cognitive therapy (MBCT) has demonstrated effectiveness in reducing these symptoms. Electronic health MBCT (eMBCT) offers a scalable alternative, but its efficacy in alleviating anxiety and depression in adults remains unclear.</div></div><div><h3>Objectives</h3><div>To examine the treatment efficacy of eMBCT for adult anxiety and depression and identify potential moderators associated with better treatment outcomes.</div></div><div><h3>Methods</h3><div>A systematic search was conducted across PubMed, PsycINFO, Web of Science, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to February 24, 2024. RCTs comparing eMBCT with usual care, waitlist controls, or active interventions in adults with anxiety or depression were included. Two independent reviewers conducted study selection, data extraction, and risk-of-bias assessment using the Cochrane Risk of Bias Tool. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were calculated using Review Manager 5.3 and Stata 16.0 to estimate pooled effect sizes.</div></div><div><h3>Results</h3><div>Twelve RCTs (<em>n</em> = 2588) were included. eMBCT significantly reduced anxiety (SMD = −0.33, 95 % CI [−0.52, −0.15], <em>P</em> &lt; 0.001) and depression (SMD = −0.34, 95 % CI [−0.50, −0.17], P &lt; 0.001), with both effects representing a small effect size. Subgroup analysis showed significant short- and long-term effects, but no medium-term benefits. Greater baseline symptom severity was associated with larger improvements.</div></div><div><h3>Conclusions</h3><div>eMBCT effectively alleviates anxiety and depression, with sustained benefits. Future research should enhance its medium-term and long-term effectiveness of eMBCT and explore relevant intervention features that offer patients more flexible and personalized care.</div><div><em>Registration number</em>: CRD42024544712 (PROSPERO).</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 211-222"},"PeriodicalIF":4.1,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating cardiorespiratory fitness in people with psychotic disorders","authors":"Justin Chapman ,&nbsp;Justin Holland ,&nbsp;Nicole Korman ,&nbsp;Robert Mullins ,&nbsp;Meg Doohan ,&nbsp;Steve Koh ,&nbsp;Rob Robergs","doi":"10.1016/j.genhosppsych.2025.07.018","DOIUrl":"10.1016/j.genhosppsych.2025.07.018","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 199-200"},"PeriodicalIF":4.1,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive psychology interventions applied to the treatment of substance use disorder: A systematic review","authors":"Enrique Rubio-Escobar ,&nbsp;Covadonga Chaves Vélez ,&nbsp;Miguel Ángel Pérez Nieto","doi":"10.1016/j.genhosppsych.2025.07.012","DOIUrl":"10.1016/j.genhosppsych.2025.07.012","url":null,"abstract":"<div><h3>Background</h3><div>Relapse prevention techniques for substance use disorders (SUD) show low long-term effectiveness. Positive Psychology-based Interventions (PPIs), which enhance well-being and personal growth, have shown promising effects in other disorders but remain underexplored in SUD<strong>.</strong></div></div><div><h3>Objective</h3><div>To explore the preliminary effects of PPIs in the SUD population and which types of interventions are most useful.</div></div><div><h3>Methodology</h3><div>A systematic review following PRISMA guidelines included 12 empirical studies from various databases.</div></div><div><h3>Results</h3><div>Although only 6.2% of screened articles met inclusion criteria, their methodological quality was high. Improvements in hedonic emotional states were observed in 7 out of 9 studies (77.77%) and in all 3 studies evaluating eudaimonic states. Significant reductions in substance use variables occurred in 5 out of 9 studies.</div></div><div><h3>Conclusions</h3><div>PPIs show preliminary promise as complementary tools for the treatment of SUD, although research is needed.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 201-210"},"PeriodicalIF":4.1,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic stimulus for households during the COVID-19 pandemic may have mitigated rise in overdose deaths","authors":"Robin Ghertner ,&nbsp;Mir M. Ali","doi":"10.1016/j.genhosppsych.2025.07.019","DOIUrl":"10.1016/j.genhosppsych.2025.07.019","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 193-194"},"PeriodicalIF":4.1,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}